In comparison to anti-TNFRSF14 mono-treatment, the combination of TNFRSF14 and PD-L1 blockade remarkably extend the survival of tumor-bearing mice (Fig. 6H and Figure S7B). The gene discussed is TNFRSF14; the disease is neoplasm.